Each one, GLP-1, GIP, and glucagon, behaves differently, so endpoints and analytics need care
Life Sci (2021) 264:118645
This dual approach addresses both sides of the energy balance equation, explaining the unprecedented 24% weight loss achieved in clinical trialssignificantly exceeding the 15-20% typically achieved with appetite suppression alone
For context, the best results with semaglutide top out around 15 to 17 percent, and tirzepatide reaches approximately 20 to 22 percent
Keeping abreast of these developments is critical as they pave the way for a new paradigm in treatment
Additional clinical trials are in progress, including the investigation of GLP-1s to treat glaucoma, Friedreich ataxia, and multiple sclerosis